Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deus RapidScreen Becomes First CAD To Gain FDA Approval For Lung Cancer

This article was originally published in The Gray Sheet

Executive Summary

The integration of Deus Technologies' RapidScreen RS-2000 computer-aided diagnosis (CAD) software for lung cancer into Marconi Medical Systems' imaging devices could be facilitated by a recent U.S. distribution agreement between the companies.
Advertisement

Related Content

GEMS/Deus
GEMS/Deus
Deus/GEMS
Deus/GEMS
R2 $86 Mil. Offering Would Fund LungCheck CAD Software Development
R2 $86 Mil. Offering Would Fund LungCheck CAD Software Development
Marconi Medical Systems $1.1 Bil. Divestiture Ends Philips' Shopping Spree
Jubilate Deus: RapidScreen CAD Receives Favorable Panel Review
Jubilate Deus: RapidScreen CAD Receives Favorable Panel Review
Advertisement
UsernamePublicRestriction

Register

MT015207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel